Table 1.
Primary results for MR analysis of circulating cytokines on sepsis.
| Method | Beta | SE | OR | 95% CI | P -value | |
|---|---|---|---|---|---|---|
| CTACK levels | Inverse variance weighted | -0.006 | 0.026 | 0.994 | 0.944-1.046 | 0.812 |
| beta-nerve growth factor levels* | Inverse variance weighted | 0.114 | 0.040 | 1.120 | 1.037-1.211 | 0.004 |
| Vascular endothelial growth factor levels | Inverse variance weighted | 0.035 | 0.041 | 1.036 | 0.956-1.122 | 0.392 |
| Macrophage Migration Inhibitory Factor levels | Inverse variance weighted | 0.009 | 0.037 | 1.009 | 0.939-1.084 | 0.812 |
| TRAIL levels | Inverse variance weighted | 0.016 | 0.022 | 1.016 | 0.974-1.060 | 0.468 |
| Tumor necrosis factor beta levels | Inverse variance weighted | 0.022 | 0.029 | 1.022 | 0.966-1.081 | 0.449 |
| Tumor necrosis factor alpha levels | Inverse variance weighted | -0.007 | 0.049 | 0.993 | 0.903-1.092 | 0.883 |
| Stromal-cell-derived factor 1 alpha levels | Inverse variance weighted | 0.040 | 0.053 | 1.041 | 0.938-1.156 | 0.450 |
| Stem cell growth factor beta levels | Inverse variance weighted | 0.015 | 0.029 | 1.015 | 0.960-1.074 | 0.600 |
| Stem cell factor levels | Inverse variance weighted | -0.040 | 0.055 | 0.961 | 0.863-1.070 | 0.471 |
| Interleukin-16 levels | Inverse variance weighted | -0.031 | 0.023 | 0.970 | 0.928-1.014 | 0.176 |
| RANTES levels* | Inverse variance weighted | -0.083 | 0.041 | 0.920 | 0.849-0.997 | 0.041 |
| Platelet-derived growth factor BB levels | Inverse variance weighted | 0.052 | 0.037 | 1.053 | 0.980-1.133 | 0.160 |
| Macrophage inflammatory protein 1b levels | Inverse variance weighted | -0.027 | 0.021 | 0.973 | 0.934-1.013 | 0.184 |
| Macrophage inflammatory protein 1a levels | Inverse variance weighted | -0.017 | 0.045 | 0.983 | 0.900-1.073 | 0.698 |
| Monokine induced by gamma interferon levels | Inverse variance weighted | 0.000 | 0.029 | 1.000 | 0.945-1.059 | 0.992 |
| Macrophage colony stimulating factor levels | Inverse variance weighted | -0.047 | 0.026 | 0.954 | 0.907-1.003 | 0.065 |
| Monocyte chemoattractant protein-3 levels | Inverse variance weighted | -0.039 | 0.033 | 0.962 | 0.902-1.026 | 0.237 |
| Monocyte chemoattractant protein-1 levels | Inverse variance weighted | -0.058 | 0.033 | 0.944 | 0.885-1.007 | 0.079 |
| Interleukin-12p70 levels | Inverse variance weighted | 0.022 | 0.035 | 1.022 | 0.956-1.094 | 0.520 |
| Interferon gamma-induced protein 10 levels | Inverse variance weighted | -0.055 | 0.035 | 0.947 | 0.885-1.013 | 0.115 |
| Interleukin-18 levels | Inverse variance weighted | -0.008 | 0.021 | 0.992 | 0.952-1.034 | 0.718 |
| Interleukin-17 levels | Inverse variance weighted | 0.048 | 0.056 | 1.049 | 0.939-1.172 | 0.393 |
| Interleukin-13 levels | Inverse variance weighted | 0.034 | 0.038 | 1.034 | 0.960-1.114 | 0.373 |
| Interleukin-10 levels | Inverse variance weighted | 0.010 | 0.044 | 1.010 | 0.927-1.100 | 0.827 |
| Interleukin-8 levels | Inverse variance weighted | -0.060 | 0.044 | 0.941 | 0.864-1.025 | 0.166 |
| Interleukin-6 levels | Inverse variance weighted | -0.100 | 0.052 | 0.905 | 0.818-1.002 | 0.055 |
| Interleukin-1-receptor antagonist levels | Inverse variance weighted | -0.044 | 0.039 | 0.957 | 0.887-1.033 | 0.259 |
| Interleukin-1-beta levels | Inverse variance weighted | -0.019 | 0.056 | 0.981 | 0.879-1.095 | 0.732 |
| Hepatocyte growth factor levels | Inverse variance weighted | 0.002 | 0.073 | 1.002 | 0.869-1.155 | 0.980 |
| Interleukin-9 levels | Inverse variance weighted | -0.025 | 0.055 | 0.975 | 0.875-1.086 | 0.647 |
| Interleukin-7 levels | Inverse variance weighted | 0.030 | 0.025 | 1.030 | 0.982-1.082 | 0.225 |
| Interleukin-5 levels | Inverse variance weighted | -0.039 | 0.055 | 0.962 | 0.864-1.072 | 0.484 |
| Interleukin-4 levels | Inverse variance weighted | 0.080 | 0.044 | 1.083 | 0.994-1.180 | 0.070 |
| Interleukin-2 receptor antagonist levels | Inverse variance weighted | -0.006 | 0.027 | 0.994 | 0.943-1.049 | 0.833 |
| Interleukin-2 levels | Inverse variance weighted | 0.018 | 0.035 | 1.018 | 0.951-1.090 | 0.609 |
| Interferon gamma levels | Inverse variance weighted | -0.035 | 0.048 | 0.966 | 0.879-1.061 | 0.472 |
| Growth-regulated protein alpha levels | Inverse variance weighted | 0.014 | 0.028 | 1.014 | 0.959-1.071 | 0.628 |
| Granulocyte-colony stimulating factor levels | Inverse variance weighted | -0.048 | 0.037 | 0.953 | 0.887-1.024 | 0.189 |
| Fibroblast growth factor basic levels* | Inverse variance weighted | -0.141 | 0.065 | 0.869 | 0.766-0.986 | 0.029 |
| Eotaxin levels | Inverse variance weighted | -0.041 | 0.034 | 0.960 | 0.898-1.027 | 0.232 |
MR, mendelian randomization; SE, standard error; OR, odds ratio; CI, confdence interval; CTACK, cutaneous T-cell attracting (CCL27); RANTES, regulated on activation, normal T-cell expressed and secreted (CCL5); TRAIL TNF-related apoptosis-inducing ligand.
The * symbol represents a p-value of less than 0.05, which is statistically significant.
Bold values represent p-values less than 0.05, which is statistically significant.